Tilray Inc. (TLRY)

70.19
0.40 0.57
NASDAQ : Health Technology
Prev Close 69.79
Open 69.39
Day Low/High 68.25 / 71.25
52 Wk Low/High 20.10 / 300.00
Volume 1.40M
Avg Volume 2.74M
Exchange NASDAQ
Shares Outstanding 76.50M
Market Cap 6.73B
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dow Ends Down on Report China Is Pushing Back During Trade Talks

Dow Ends Down on Report China Is Pushing Back During Trade Talks

Stocks ended mixed Tuesday on reports that China may be pushing back against American trade talk demands.

Pot Stocks Trade Mixed Following Tilray's Fourth-Quarter Results

Pot Stocks Trade Mixed Following Tilray's Fourth-Quarter Results

Tilray shares turn following the company's fourth-quarter results while other pot stocks trade mixed.

Cause for Caution? Top Executives Selling Tilray Stock

Cause for Caution? Top Executives Selling Tilray Stock

It might not be time to panic yet about Tilray, but there's likely a problem ahead.

With Tilray, You Won't Win Any Valuation Arguments

With Tilray, You Won't Win Any Valuation Arguments

Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.

Trading Tilray Stock's Wild Post-Earnings Volatility

Trading Tilray Stock's Wild Post-Earnings Volatility

Tilray's wide trading range on Tuesday is relatively calm considering the important levels it's teetering on.

Tilray Sales Beat Estimates but Shares Turn Lower

Tilray Sales Beat Estimates but Shares Turn Lower

Tilray turns lower after the Canadian cannabis group posts a wider-than-expected fourth-quarter loss but says sales nearly tripled in a growing global market for medical marijuana.

How Jim Cramer Felt About Tilray's Earnings Call

How Jim Cramer Felt About Tilray's Earnings Call

Jim Cramer says that Tilray's earnings call disappointed him. Here's why he wasn't blown away.

Tilray Touts Global Ambition as Erosion of Canadian Market Expected

Tilray Touts Global Ambition as Erosion of Canadian Market Expected

A key aspect of the international expansion is the company's recent acquisition of hemp-food producer Manitoba Harvest in February.

Tilray Is Not My Favorite Canadian Cannabis Stock

Tilray Is Not My Favorite Canadian Cannabis Stock

Apparently, this game is all about growth right now. It certainly is not about margins.

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.

Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

Here's what you need to know about Tilray's earnings, Elon Musk's fight with the SEC and Bristol-Myers fight with Starboard over Celgene. Jim Cramer talks the markets

Tilray Has Rebased and Looks Poised to Rally Again - Consider Buying Strength

Tilray Has Rebased and Looks Poised to Rally Again - Consider Buying Strength

Let's check out the charts and indicators for this so-called pot play.

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.

Elon Musk, Tilray, the Federal Reserve and Nvidia - 5 Things You Must Know

Elon Musk, Tilray, the Federal Reserve and Nvidia - 5 Things You Must Know

U.S. stock futures rise modestly ahead of the start of the two-day Federal Reserve meeting; the SEC blasts Tesla CEO Elon Musk for his alleged failure to abide by an agreement to curb his 'reckless' tweets; cannabis company Tilray beats revenue estimates.

Tilray Rises Sharply on Revenue Beat

Tilray Rises Sharply on Revenue Beat

Tilray shares rose in after-hours action on strong revenue as traders shrugged off a wider-than-expected loss.

Tilray, Inc. Reports Full Year 2018 Financial Results

Tilray, Inc. Reports Full Year 2018 Financial Results

Tilray, Inc., ("Tilray" or the "Company") (Nasdaq: TLRY) a global leader in cannabis research, cultivation, production and distribution, today reported financial results for the fourth quarter and year ended December 31, 2018.

Here's How Tilray Is Doing Ahead of Monday's Earnings Release

Here's How Tilray Is Doing Ahead of Monday's Earnings Release

Tilray is expected to increase its revenue by more than 50% from the previous quarter.

The Future of Cannabis: Edibles & Oil Based Products

The Future of Cannabis: Edibles & Oil Based Products

When it comes to products related to cannabis consumption, a rich universe of options continues to scale up around oils and edibles.

General Motors, Boeing, Worldpay, Caesars and the Fed - 5 Things You Must Know

General Motors, Boeing, Worldpay, Caesars and the Fed - 5 Things You Must Know

U.S. stock futures are mixed on Monday; the Federal Reserve is unlikely to lift interest rates when it meets this week; a meeting between Donald Trump and Chinese President Xi Jinping may be pushed off until June, a report says.

3 Important Earnings Reports I'll Be Watching This Week

3 Important Earnings Reports I'll Be Watching This Week

This quarter is a heavy test for Tilray because of the stock's lofty valuation.

How Tilray Can Pass Its First Major Test of 2019

How Tilray Can Pass Its First Major Test of 2019

Tilray is scheduled to report fourth-quarter results after the closing bell Monday.

Chart of the Day: Vetting the Value of Cannabis Companies

Chart of the Day: Vetting the Value of Cannabis Companies

Assessing Aurora and its peers, strictly on the numbers.

Aurora Cannabis' Is a Beast but the Stock Has Entered a Tricky Area Now

Aurora Cannabis' Is a Beast but the Stock Has Entered a Tricky Area Now

Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.

Jim Cramer: Buy Aurora Cannabis Because Nelson Peltz Knows What Can Go Right

Jim Cramer: Buy Aurora Cannabis Because Nelson Peltz Knows What Can Go Right

I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.

Aurora Is an 'Undervalued Company,' Says Jim Cramer

Aurora Is an 'Undervalued Company,' Says Jim Cramer

Jim Cramer discusses Real Money's stock of the day and why he believes that the company is undervalued.

Aurora Cannabis Could Triple in the Months Ahead

Aurora Cannabis Could Triple in the Months Ahead

The price of ACB is moving up today and a fresh look at the charts and indicators seems like a good idea.

Andrew Pucher, Chief Corporate Development Officer, Tilray (Photo: Business Wire)

Andrew Pucher, Chief Corporate Development Officer, Tilray (Photo: Business Wire)

Today, Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announces the expansion of its global senior leadership team with the appointment of Andrew Pucher as Chief Corporate Development Officer.